Find Academic Supervisors

Thomas Perlmann is a Professor in Molecular Developmental Biology at the Karolinska Institutet , leading research at the Department of Cell and Molecular Biology and serving as Director of the Stockholm Branch of the Ludwig Institute for Cancer Research. He also holds the position of Secretary General of the Nobel Assembly and Nobel Committee for Physiology or Medicine since 2016. Ph.D. , Karolinska Institutet, 1991 M.Sc. , Stockholm University, 1987 Research Interests : The Perlmann lab investigates the specification and maintenance of dopamine neurons in the central nervous system, with a focus on transcriptional regulation , signaling pathways , and regenerative medicine applications for Parkinson’s disease and other neurodegenerative disorders. His work bridges developmental biology and neuroscience , emphasizing the role of transcription factors in neuronal identity and function. Recent Research Trends : Perlmann’s recent publications highlight the use of single-cell RNA sequencing to dissect dopamine neuron heterogeneity , epigenetic regulation during development, and transcriptomic changes in Parkinson’s disease models. His studies increasingly leverage multiomics and bioinformatics to map neuronal lineage trajectories and gene expression dynamics. Scientific Awards : Royal Medal by HM the King (2025) Nicholson Lecturer, Rockefeller University (2011) Göran Gustafsson Prize in Molecular Biology (1999) Eric K. Fernström Young Investigator Prize (1997) Advising & Collaborations : While no student names are explicitly listed, Perlmann collaborates extensively with researchers such as Malin Parmar , Agnete Kirkeby , and Per Svenningsson on projects related to neuronal development and cell therapy . His lab receives funding from institutions like the Ludwig Institute for Cancer Research . Labs & Teams : The Perlmann Lab at Karolinska Institutet includes researchers like Linda Gillberg , Laura Lahti , and Behzad Yaghmaeian Salmani , who work on mouse models , single-cell transcriptomics , and bioinformatics to study dopamine neuron biology.

• Developmental Biology
• Neurosciences
• Dopamine Neurons
• +4 more

Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.

• Stem Cell Biology
• Genetic Engineering
• Epigenetics
• +5 more

Christopher E. Nelson is an Assistant Professor in the Department of Biomedical Engineering at the University of Arkansas, College of Engineering. His lab focuses on developing biologically inspired strategies for controlled drug and gene delivery, particularly in the context of gene therapy and regenerative medicine. He is actively supported by the NIH, DoD, and Arkansas Bioscience Institute. Education: Postdoctoral Fellow – Duke University Ph.D. – Vanderbilt University B.S. – University of Arkansas Research Focus: Dr. Nelson’s lab integrates genome editing technologies with targeted delivery systems to address challenges in treating genetic diseases and promoting tissue regeneration. Major themes include CRISPR/Cas9 delivery , gene regulation in wound healing , and safe-harbor genome integration in skeletal muscle. His work spans viral and non-viral delivery vehicles , including lipid nanoparticles and AAV vectors, with a strong emphasis on preclinical validation in models of Duchenne muscular dystrophy and inflammatory disease. Scientific Awards: Controlled Release Society Postdoctoral Fellowship The Hartwell Foundation Postdoctoral Fellowship NIH Pathway to Independence Award (K99/R00) Funding & Support: The Nelson Lab is currently funded by: NIH NIGMS R35 DoD CDMRP DMD IDEA Award Arkansas Bioscience Institute University of Arkansas Engineering & Honors Colleges Lab & Team: The Nelson Lab is a dynamic, interdisciplinary team working at the intersection of gene editing, biomaterials, and regenerative medicine. They regularly present at national conferences such as ASGCT and NCUR, and mentor undergraduate researchers through SURF and Honors College grants.

• Gene therapy
• Regenerative medicine
• Genome editing
• +7 more

Hang Lu is an Associate Professor in the Department of Communication and Media at the University of Michigan's College of Literature, Science, and the Arts. He specializes in science, health, environmental, and risk communication (ComSHER), with a focus on media psychology. His research explores audience responses to media messages about sensitive topics and strategies to enhance message effectiveness. Lu holds a Ph.D. in Communication from Cornell University (2018), along with advanced degrees from Cornell, Marquette University, and Central South University in China. He directs the Media and Risk (MaR) Lab and previously served as a postdoctoral fellow at the Annenberg Public Policy Center. His research spans four main areas: 1) emotion dynamics in media responses, 2) predictors of information behaviors, 3) media effects on stigmatization, and 4) AI applications in sensitive domains. He has published in journals like Journal of Communication , Risk Analysis , and Public Understanding of Science , earning multiple top paper awards. As Vice Chair of the Environmental Communication Division at the International Communication Association, Lu contributes to interdisciplinary dialogue. His work addresses critical societal issues such as climate change communication, vaccination hesitancy, and emerging technology ethics.

• Science Communication
• Health Communication
• Environmental Communication
• +4 more

Professor Richard Wade-Martins is a leading academic in University of Oxford 's Department of Physiology, Anatomy and Genetics . He directs the Molecular Neurodegeneration Research Laboratory and the Oxford Parkinson’s Disease Centre (OPDC). With degrees from Cambridge (MA) and Oxford (DPhil), he has held prestigious fellowships including Wellcome Trust Research Career Development Fellowship and NIH reviewer roles. His research targets molecular mechanisms in Parkinson’s and Alzheimer’s diseases through iPSC models , transgenic mice , and lysosomal function studies . He pioneered work on SNCA , MAPT , and LRRK2 gene pathways. Current projects focus on gene therapy and mitochondrial dysfunction in neurodegeneration. Key publications (2019–2025) reveal trends in single-cell transcriptomics , calcium channel inhibition , and TFEB/TFE3 lysosome modulation . His awards include Wellcome Trust Fellowships and advisory roles for Parkinson's UK , Alzheimer's Research UK , and EU consortia like StemBANCC and EFACTS . He leads the UK Dementia Platform iPSC Initiative and serves on international boards in Luxembourg and Canada.

• Neurodegenerative Diseases
• Molecular Neuroscience
• Stem Cell Research
• +3 more

Gary Gibson is a tenured Professor of Neuroscience at Weill Cornell Medicine and serves as Lab Director at the Burke Neurological Institute . He leads the Laboratory for Mitochondrial Biology and Metabolic Dysfunction in Neurodegeneration , focusing on age-related neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's disease . Educational background: Ph.D. in Physiology (Biochemistry/Neuroscience), Cornell University B.S. in Zoology and Chemistry, University of Wyoming His research investigates how mitochondrial dysfunction , reduced glucose metabolism , and oxidative stress contribute to neurodegeneration. He explores therapeutic interventions targeting these mechanisms, including benfotiamine for improving thiamine levels and modulating post-translational modifications of mitochondrial enzymes like the α-ketoglutarate dehydrogenase complex (KGDHC) . These studies integrate human autopsy samples, genetically modified cells , and transgenic mouse models to test hypotheses about calcium dysregulation, free radical damage, and inflammatory cascades. Recent publications highlight his work on mitochondrial enzyme plasticity , nutritional metabolism in dementia, and benfotiamine's neuroprotective effects in clinical trials. He has secured continuous NIH funding (Grant R01AG043679) and holds three U.S. patents . Dr. Gibson serves on editorial boards for Neurochemical Research , Neurochemical International , and Journal of Neurochemistry , and has mentored undergraduate students and postdoctoral researchers .

• Neurodegeneration
• Alzheimer's Disease
• Parkinson's Disease
• +7 more

Kassandra Kisler Elliott, PhD, is an Assistant Professor of Research Physiology & Neuroscience at the University of Southern California. She serves as Assistant Director of the Optical Imaging Core and Research Operations at the Center for Neurodegeneration and Regeneration, Zilkha Neurogenetic Institute. PhD in Applied Physics from Cornell University Her research focuses on the neurovascular unit, blood-brain barrier integrity, and microvascular dysfunction in neurodegenerative diseases. She develops in vivo imaging techniques to study vascular dynamics in real-time, particularly in transgenic models of Alzheimer's disease. Her 2020 publication introduced a novel toolset for visualizing whole mouse brain vasculature, reflecting her expertise in imaging and vascular biology. In her role at the Zlokovic lab, she investigates Alzheimer's disease risk genes (APOE4, PICALM) using transcriptomics and traditional methods, bridging vascular biology with neurodegenerative disease research.

• Neurovascular unit
• Blood-brain barrier integrity
• Microvascular dysfunction in dementia
• +3 more

Dr. Neashan Mathavan is a Lecturer in the Department of Health Sciences and Technology at ETH Zürich, affiliated with the Institut für Biomechanik . His research focuses on musculoskeletal biomechanics, aging-related bone deterioration, and spatial omics approaches to study fracture healing and mechanoregulation. He has pioneered work on mouse models of premature aging (e.g., PolgA mice) to investigate sex-specific mechanisms of bone regeneration and frailty. Key areas include spatial transcriptomics, osteocyte function, and the role of mechanical loading in musculoskeletal repair. Dr. Mathavan’s research integrates advanced imaging techniques (e.g., spatial μProBe, super-resolution spatial transcriptomics) with biomechanical testing to elucidate molecular and structural changes in aging bones. His recent studies emphasize the interplay between mechanical signals and molecular pathways in bone regeneration, particularly in contexts like osteoporosis and osteoarthritis. He has also developed novel osteochondral explant models to study cartilage-bone crosstalk in osteoarthritis. His publications span 2009–2025, with a focus on translational studies linking mechanobiology to clinical outcomes. Notable contributions include investigating the efficacy of BMP-7 and zoledronate therapies in bone regeneration, as well as the role of IL-1β in osteochondral tissues. His work has implications for personalized therapies targeting musculoskeletal aging and degenerative diseases. Dr. Mathavan supervises PhD students like Riyin Tay, who explored palliative care for advanced dementia patients. He collaborates on grants involving biomechanical modeling, spatial omics, and transgenic mouse models. His laboratory at ETH Zürich’s Institut für Biomechanik is equipped for advanced imaging, mechanical testing, and molecular biology.

• Biomechanics
• Bone Biology
• Regenerative Medicine
• +3 more

Dr. Barbara L. Hempstead is a Professor of Neuroscience and Medicine at Weill Cornell Medical College, where she has held positions since 2001 and 2002 respectively. Her research focuses on neurotrophin signaling mechanisms, particularly the roles of BDNF and its receptors in neuroinflammation, synaptic plasticity, and neurodegenerative diseases. She has made significant contributions to understanding proBDNF/proNGF signaling pathways in neuronal apoptosis and vascular biology. Education: M.D., Ph.D., Washington University School of Medicine (1982) B.A., Tufts University (1976) Dr. Hempstead's work bridges molecular neuroscience and cardiovascular biology, with a particular interest in receptor stoichiometry (p75NTR, TrkB), neurotrophin-induced synaptic remodeling, and therapeutic applications of neurotrophin modulators in Huntington's disease and post-seizure neuronal injury. Her lab investigates how genetic variants like BDNF Val66Met influence anxiety-related behaviors, social memory, and neurodegenerative disease progression through altered neurotrophin trafficking and signaling. Her recent publications highlight neuroinflammatory mechanisms (2023), immune-neurotrophin interactions (2022), and molecular pathways involving BDNF prodomain structure (2020) and SorCS2-mediated receptor trafficking (2017-2020). While no scientific awards are explicitly mentioned in the scraped text, her funded research (National Institute on Aging, NIMH) demonstrates sustained recognition of her work in neurotrophin biology. Dr. Hempstead's lab develops in vitro and in vivo models to study neurotrophin-receptor dynamics, including 3D culture systems for angiogenesis research and transgenic mouse models for Huntington's disease. Her interdisciplinary approach combines molecular neurobiology with vascular physiology to uncover novel therapeutic targets for neurological and cardiovascular conditions.

• Neuroscience
• Neurotrophin Signaling
• Neurodegenerative Diseases
• +5 more

Jingwei Cheng is an Assistant Professor in the Department of Molecular, Cellular, and Biomedical Sciences at the University of New Hampshire's College of Life Sciences and Agriculture. His research focuses on understanding the molecular mechanisms of DNA tumor viruses, particularly polyomaviruses, and their roles in cancer development. Specifically, his work investigates how Merkel cell polyomavirus (MCV) contributes to Merkel cell carcinoma (MCC) through interactions with tumor suppressors like p53 and RB, and the epigenetic regulation of transcriptional complexes. Cheng completed his B.S. in Biotechnology at Peking University and earned his Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign. His lab explores viral oncogenesis, MYC-driven cancers, and the interplay between transcriptional activation (via the SLaP complex) and repression (via PRC1.6) in neuroendocrine tumors. He also studies RNA methylation and splicing regulation in cancer cells with MYC overexpression. Cheng's research has identified druggable targets such as PRMT5 and the Tip60-p400 complex, aiming to develop therapies targeting MYC-driven cancers. His work bridges virology and cancer biology, with implications for neuroendocrine tumors like MCC and small cell lung cancer. He teaches courses on virology and cancer biochemistry and mentors students in molecular oncology research. His recent publications focus on viral mechanisms of immune evasion, molecular markers in MCC subtypes, and the therapeutic potential of targeting viral and epigenetic pathways. Cheng collaborates on genome-scale CRISPR screens and omics technologies to uncover cancer dependencies.

• Virology
• Cancer Biology
• Epigenetics
• +7 more

Maria Golson, PhD, is an Assistant Professor of Medicine in the Division of Endocrinology, Obesity and Metabolism at the Johns Hopkins School of Medicine. She joined the institution in 2020 and leads research focused on the intrinsic and extrinsic regulation of beta-cell function and insulin secretion. Her work is central to understanding pancreatic endocrine cell development and its implications in diabetes. Education: B.S. in Biology (Genetics concentration), Duke University, 2000 Ph.D. in Cell and Molecular Biology (Genetics and Gene Regulation), University of Pennsylvania, 2008 Postdoctoral Training, Vanderbilt University Dr. Golson's research spans molecular mechanisms of beta-cell function, epigenetic regulation in diabetes, and single-cell analysis of pancreatic islets. She employs advanced genomic and epigenomic tools to explore cellular states in both type 1 and type 2 diabetes, with a focus on identifying pathways that could be targeted for regeneration or functional enhancement of insulin-producing cells. Her recent publications, appearing in journals such as Nature Metabolism and Diabetes , reflect a strong trend toward multiomics and single-cell technologies to uncover novel cellular states in human islets. These studies integrate transcriptomics, epigenetics, and functional validation to dissect disease mechanisms. Dr. Golson has been supported by institutional affiliations and collaborations, including membership in the HPAP Consortium and the American Diabetes Association. While no formal awards are listed, her publication record indicates significant scientific contributions. She has mentored researchers through collaborative projects, though no formal advisees are named. Her lab engages in interdisciplinary research involving genetics, molecular biology, and bioinformatics to advance diabetes therapeutics.

• Endocrinology
• Beta-cell Function
• Insulin Secretion
• +6 more

Amjad Javed is a Professor and Associate Dean at the University of Alabama at Birmingham , with primary appointments in the School of Dentistry - Oral & Maxillofacial Surgery and joint affiliations in Cell, Developmental and Integrative Biology , Otolaryngology , and Biomedical Engineering . His research spans bone biology, cartilage development, and myeloma bone disease. PhD in Physiology (University of the Punjab, 2003) MS in Zoology/Animal Biology (University of the Punjab, 1992) Research Interests focus on transcriptional regulation via RUNX2 and Sp7 in skeletogenesis, vascular calcification mechanisms, epigenetic control of bone formation, and tumor-bone microenvironment interactions in multiple myeloma. Key subfields include endochondral ossification, osteoclast differentiation, and nanomatrix-based tissue engineering. Scientific Contributions include discoveries about RUNX2's role in postnatal bone resorption, λ5 protein's impact on skeletal aging, and heparanase's promotion of myeloma metastasis. His work demonstrates RUNX2's dual function in chondrocyte apoptosis and cartilage degradation. Teaching & Mentorship involves graduate committee service for over 15 students and instruction in courses like Connective Tissue and Bone , Oral & Skeletal Biology , and Journal Clubs . Collaborations span Comprehensive Arthritis, Musculoskeletal, Bone and Autoimmunity Center , Integrative Center for Aging Research , and Biomatrix Eng Regen Med Center .

• Bone Biology
• Cartilage Development
• Transcriptional Regulation
• +4 more

Sachi Horibata is an Assistant Professor in the Department of Pharmacology & Toxicology at Michigan State University (MSU), affiliated with the College of Human Medicine. She is also associated with the Precision Health Program and the Neuroscience Program. Her research focuses on cancer biology, drug discovery, and computational genomics, with a particular emphasis on understanding mechanisms of drug resistance in cancers like acute myeloid leukemia (AML) and breast cancer. Dr. Horibata’s work integrates proteomics, transcriptomics, and cellular models to uncover therapeutic targets and biomarkers. She holds a PhD in Biological and Biomedical Sciences from Cornell University (2010–2016). Her research interests include genomic analysis of cancer heterogeneity, enzyme-driven cancer progression (e.g., PAD enzymes), and immune evasion mechanisms in tumors. Her recent studies highlight the role of protein citrullination in cancer cell migration and endocrine resistance. Dr. Horibata’s publications span topics in oncology, immunology, and molecular biology, with a focus on translational research. She teaches PHM 802: Cellular, Molecular and Integrated Systems Pharmacology. Her lab is located in the Interdisciplinary Science and Technology Building at MSU.

• Cancer Biology
• Drug Discovery
• Computational Genomics
• +3 more

Alison Elder, Ph.D., is an Associate Professor in the Department of Environmental Medicine at the University of Rochester School of Medicine and Dentistry. She is affiliated with several research programs including the Environmental Health Sciences Center, the Inhalation Exposure Facility, the Toxicology Training Program (as Co-Director), the Lung Biology and Disease Program, and the Multidisciplinary Training in Pulmonary Research Program. Her research focuses on the toxicology of inhaled ultrafine particles (UFPs) and engineered nanomaterials, with implications for pulmonary, cardiovascular, and central nervous system health. Ph.D. in Environmental Toxicology, University of California, Irvine (1997) B.S. in Chemistry, Chatham College (1992) Post-doctoral Fellow, Department of Environmental Medicine, University of Rochester (1997–2000) Dr. Elder’s research centers on the health impacts of airborne particulate matter, particularly how age, co-pollutants, and health status influence responses to inhaled particles. Her work explores the translocation of particles to extrapulmonary tissues, including the brain, and their role in neurodegenerative diseases like Alzheimer’s. She investigates mechanisms such as oxidative stress, inflammation, and glymphatic dysfunction. Her lab also studies airborne micro- and nanoplastics, focusing on exposure characterization and health implications. Her recent publications span topics including Alzheimer’s disease models, glymphatic impairment, nanoparticle dissolution, and diesel exhaust effects on lung barriers. These works emphasize particle-induced inflammation, neurotoxicity, and the intersection of environmental exposure with neurological outcomes. Young Investigator Award, Society of Toxicology (2009) Cornerstone Alumna Award, Chatham University (2007) Graduate Student Fellowship, U.S. EPA (1995–1996) College Chemistry Award, Society for Analytical Chemists of Pittsburgh (1992) Dr. Elder mentors graduate students in toxicology and has trained numerous postdoctoral fellows and technicians. She leads an active research laboratory funded by NIH and DOD, investigating air pollution’s role in brain health and military burn pit exposures. Her collaborative research includes work with experts in neuroscience, materials science, and environmental engineering. She is also involved in national workshops on nanomaterial risk assessment and children’s environmental health. She leads the Elder Lab, which conducts studies on air pollution and Alzheimer’s disease, characterizes airborne micro- and nanoplastics, and develops models for nanoparticle toxicity. The lab uses advanced techniques in particle characterization, animal modeling, and cellular assays to assess health risks.

• Toxicology of Inhaled Ultrafine Particles
• Engineered Nanomaterials
• Air Pollution and Neurodegeneration
• +12 more

Edward Gunther, MD is a Professor in the Department of Medicine, Division of Hematology and Oncology at Penn State College of Medicine and the Penn State Cancer Institute. His research focuses on breast cancer mechanisms using genetically modified mouse models to uncover molecular and cell biological mechanisms of cancer development and progression. His research interests include: Breast cancer progression and relapse mechanisms Transgenic mouse modeling of mammary tumors Oncogene function in carcinogenesis Tumor cell heterogeneity and subclone cooperation Minimal residual disease and dormancy Dr. Gunther's recent publications reveal how different oncogenes shape premalignant clone progression in breast cancer models, mechanisms of relapse-proficient subclones with collateral sensitivity to oncogene overdose, and carcinogen-specific mutation patterns in Ras-Raf pathway oncogenes. His work demonstrates how reproductive history influences cancer development and how long-lived premalignant clones can evade natural protective mechanisms. His scientific recognition includes: Outstanding Research Publication award (2014) for his Nature paper on tumor heterogeneity Substantial social media and academic engagement for his research (658 Mendeley readers for the Nature paper) Dr. Gunther has received continuous National Cancer Institute funding as Principal or Co-Principal Investigator for multiple projects spanning nearly two decades: Genetic Analysis of Breast Cancer Progression in Mice Using Inducible Transposition (2017-2018) Modeling breast cancer relapse prevention in mice (2010-2016) Preclinical Modeling of Latent Breast Cancer in Mice (2005-2010) BRCA1 FUNCTION USING AN INDUCIBLE TRANSGENE (1999-2005) His laboratory at the Penn State Cancer Institute's Next-Generation Therapies division maintains an active research program investigating the molecular mechanisms of breast cancer progression, dormancy, and relapse using sophisticated genetically engineered mouse models that closely mimic human disease processes.

• Breast Cancer Research
• Oncology
• Molecular Biology
• +3 more